What are the medical insurance reimbursement conditions for afatinib? Which patients can benefit from

Afatinib is a targeted therapy drug mainly used to treat EGFR mutation-positive non-small cell lung cancer (NSCLC) patients. Since afatinib was launched in China, it has been included in the medical insurance reimbursement list, allowing many eligible patients to enjoy treatment with the drug through medical insurance. However, whether patients can enjoy medical insurance reimbursement is not automatically available to all patients and must meet certain conditions.

Afatinib’s medical insurance reimbursement scope is mainly for patients with non-small cell lung cancer who are positive for EGFR gene mutations. EGFR gene mutations are a common driver mutation type in non-small cell lung cancer. Afatinib can significantly improve the therapeutic effect of these patients by targeting the activity of EGFR mutants. Therefore, only patients with advanced or metastatic non-small cell lung cancer who are confirmed to have EGFR mutations through genetic testing can enjoy medical insurance reimbursement.

In addition to patients with EGFR mutation-positive non-small cell lung cancer, afatinib is also indicated for patients who have received other targeted therapies (such as erlotinib, gefitinib, etc.) but whose disease still progresses. For such patients, afatinib can be used as a second- or third-line treatment drug under the guidance of a doctor, and patients can also obtain it through medical insurance reimbursement.

It is worth noting that the specific conditions and policies for medical insurance reimbursement may vary from region to region. Medical insurance policies in different regions of China will be different. Therefore, before using afatinib, it is best for patients to consult with local hospitals or pharmacies to understand the specific reimbursement process and reimbursement ratio. Generally speaking, medical insurance reimburses afatinib at a higher rate, especially for eligible cancer patients, which can reduce the financial burden on patients.

Reference materials:https://www.giotrif.com/